САХАРНЫЙ ДИАБЕТ И БЕРЕМЕННОСТЬ. ЧАСТЬ II. ТЕЧЕНИЕ, ТАКТИКА ВЕДЕНИЯ ПАЦИЕНТОВ
Аннотация
Введение. Сахарный диабет (СД) занимает одно из первых мест в мире по распространенности и наличию осложнений. Одним из факторов, влияющих на течение сахарного диабета и его осложнений, является беременность.
Цель: изучение особенностей течения СД и его осложнений при беременности и тактика ведения беременных с СД в зависимости от срока гестации, течения СД и наличия его осложнений.
Материал и методы: проанализированы 34 литературных источника по данной тематике отечественных и зарубежных авторов.
Результаты. Установлено, что течение СД при беременности носит лабильный характер и способствует прогрессированию сосудистых осложнений у матери. Строгий контроль гликемии, введение режима многоразовых инъекций инсулина оказывает благоприятное воздействие на течение беременности и рождение здорового ребенка.
Выводы: применение интенсифицированной инсулинотерапии при ведении беременных с СД, усовершенствование тактики ведения и лечения беременных, использование современных технологий дало возможность улучшить исходы беременности для матери и плода: снизилась частота тяжелых форм гестоза, многоводия, преждевременных родов, перинатальную смертность.
Литература
Аrbatskaya NYu. Sakharnyj diabet i beremennost. Farmateka. 2000;5:30-36.
Аrzhanova ON, Kosheleva NG. Osobennosti techeniya beremennosti i rodov pri sakharnom diabete v sovremennykh usloviyakh. Zhurnal akusherstva i zhenskikh boleznej. 2006;1:12-16.
Grigoryan OR, Sheremeteva EV, Аndreeva EN, Dedov II. Planirovanie beremennosti u zhenshhin s sakharnym diabetom. Vestnik reproduktivnogo zdorovya. 2011;2:23-31.
Danilova LI, Burko II, Zabarovskaya ZV. Sakharnyj diabet i beremennost. Minsk;2010. 34 p.
Dedov II, Shestakova MV. Sakharnyj diabet: retinopatiya, nefropatiya. Moskva: Meditsina; 2001. 176 p.
Dedov II. Shestakova MV, Galstjan GR, Grigorjan OR, Esajan RM, Kalashnikov VJu, Kuraeva TL, Lipatov DV, Majorov AJu, Peterkova VA, Smirnova OM, Starostina EG, Surkova EV, Suhareva OJu, Tokmakova AJu, Shamhalova MSh, Jarek-Martynova IR. Аlgoritmy spetsializirovannoj meditsinskoj pomoshhi bolnym sakharnym diabetom. Sakharnyj diabet. 2015;18(1S):72-74.
Demidova IYu, Аrbatskaya NYu, Melnikova EP. Аktualnye problemy kompensatsii cakharnogo diabeta pri beremennosti. Sakharnyj diabet. 2009;4:32-38.
Zakharova TG, Petrova MM, Laka GP. Sakharnyj diabet i beremennost: ucheb. posobie. Krasnoyarsk: Izdatelskie linii; 2006. 126 p.
Potin VV, Borovik NV, Tiselko АV. Insulinoterapiya bolnykh sakharnym diabetom 1 tipa vo vremya beremennosti. Sakharnyj diabet. 2009;1:39-41.
Fedorova MV, Krasnopolskij VI, Petrukhin VА. Sakharnyj diabet, beremennost i diabeticheskaya fetopatiya. Moskva: Meditsina; 2001. 288 p.
Diabet i beremennost: obzor zapadnyh klinicheskih rekomendacij UpToDate. com. Chernov D, translator. 2015. 118 p.
American Diabetes Association. Standards of medical care in diabetes-2014. DiabetesCare. 2014;37(1):S14-80. doi: 10.2337/dc14-S014.
DCCT Research Group. Effects of pregnancy on microvascular complications in the Diabetic Control and Complications Trial. Diabet Care. 2000;23:1084-1100.
Crowe SM, Mastrobattista JM, Monga M. Oral glucose tolerance test and the preparatory diet. Am. J. Obstet. Gynecol. 2000;182(5):1052-1054.
Di Cianni G, Torlone E, Lencione C, Bonomo M, Di Benedetto A, Napoli A, Vitacolonna E, Mannino D, Lapolla A. Perinatal outcomes associated with the use of glargine in pregnancy. Diabet Med. 2008;25(8):993-996. doi: 10.1111/j.1464-5491.2008.02485.x.
Evers IM, de Valk HW, Mol BWJ, ter Braak EWMT, Visser GHA. Macrosomia despite good glycaemic control in Type I diabetic pregnancy; results of a nationwide study in the Netherlands. Diabetologia. 2002;45(11):1484- 1489. doi: 10.1007/s00125-002-0958-7.
The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy.Eur. Heart J.2003 ;24(11):761-781.
Gabbe SG, Holing E, Temple P, Brown ZA. Benefits, risks, costs, and patients satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am. J. Obstet Gynecol. 2000;182(6):1283.
Gallen IW, Jaap AJ, Roland JM, Chirayath IW. Survey of glargine use in 115 pregnant women with type 1 diabetes. Diabet Med. 2008:25(2):165-169.
Hellmuth E, Damm P, Molsted-Pedersen L, Bendtson I. Prevalence of nocturnal hypoglycemia in first trimester of pregnancy in patients with insulin treated diabetes mellitus. Acta Obs. Gyn. Scand. 2000;79(11):958. doi: 10.1034/j.1600-0412.2000.079011958.x.
Holing EV, Beyer CS, Brown ZA, Connell FA. Why dont women with diabetes plan their pregnancies? Diabetes Care. 1998;21(6):889-895. doi: 10.2337/diacare.21.6.889.
Home P, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabet Care.1998;21(11):1904-1909. doi.org/10.2337/diacare.21.11.1904.
Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycatedhaemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy and Childbirth. 2006.6:30. doi. org/10.1186 1471-2393-6-30.
Janz NK, Herman WH, Becker MP, Charron-Prochownik D, Shayna VL, Lesnick TG, Jacober SJ, Fachnie JD, Kruger DF, Sanfield JA, Rosenblatt SI, Lorenz RP. Diabetes and pregnancy: factors associated with seeking preconception care. Diabetes Care. 1995;18(2):157-165. doi.org/10.2337/diacare.18.2.157.
Jovanovic L, Knopp RH, Brown Z, Conley MR, Park E, Mills JL, Metzger BE, Aarons JH, Holmes LB, Simpson JL; National Institute of Child Health and Human Developtment, Diabetes in Early Pregnancy Study Group. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care. 2001;24(7):1130-1136. doi: m10.2337/diacare.24.7.1130.
Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-2148. doi: 10.2337/diabetes.49.12.2142.
Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am. J. Obstet. Gynecol. 2003;189(2):507-512.
Nielsen GL, Sorensen HT, Nielsen PH, Sabroe S, Olsen J. Glycosylated hemoglobin as predictor of adverse fetal outcome in type 1 diabetic pregnancies. Acta Diabet. 1997;34(3):217-222.
Pfutzner J, Forst T, Butzer R, Forst S, Weber MM, Pfützner AH, Pfützner A. Performance of the continuous glucosemonitoring system (CGMS) during development of ketosis in patients on insulin pump therapy. Diabet. Med. 2006;23(10):1124-1129. doi: 10.1111/j.1464-5491.2006.01945.x.
Pöyhönen-Alho M, Rönnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obs. Gyn. Scand. 2007;86(10):1124-1129. doi: 10.1080/00016340701515282.
Preventive Services Task Force. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2008;148(10):759-765.
Price N, Bartlett C, Gillmer MD. Use of insulin glargine during pregnancy: a case–control pilot study. BJOG. 2007:114(4):453-457. doi: 10.1111/j.1471-0528.2006.01216.x.
Ramin KD. Diabetic ketoacidosis in pregnancy. Obstet. Gynecol. Clin. Noth. Amer. 1999;26(3):481-487. doi: 10.1016S0889-8545(05)70092-9.
Yogev Y, Chen R, Ben-Haroush A, Phillip M, Jovanovic L, Hod M. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet. Gynecol. 2003;101(4):633-638.
